The therapeutic application of Синглон is generally in situations involving certain distressing symptoms across three core areas. The medication is commonly used to help with: long-term control of persistent asthma, symptomatic relief for seasonal and perennial allergic rhinitis, and prophylaxis against exercise-induced bronchoconstriction (EIB). This medication is applied in conditions involving inflammatory or irritative processes. For persistent asthma, it provides support that helps ease the overall symptom load and generally supports consistent respiratory function, helping to address physical discomforts such as recurrent wheezing and persistent coughing.

“Its use is relevant for easing distress and may assist with maintaining functional stability.”

For rhinitis, the medication is applied across conditions presenting with episodic manifestations, helping to address clusters of disruptive symptoms like nasal congestion, sneezing, and a runny nose. The medicine is also relevant when supportive symptom management is appropriate for EIB, which may involve managing functional strain associated with physical activity.

---

Quick Fact: Relief for Inflammatory Symptoms
Primary Focus	Conditions involving inflammatory or irritative processes in the airways.
Goal	Provides supportive relief when symptoms interfere with routine activities.
Typical Use	Daily use for maintenance and pre-exposure use for prophylaxis.

This section outlines the official population eligibility and non-eligibility rules for the medicine, as documented in regulatory labeling.

Populations for Whom Use is Prohibited

Category	Official Regulatory Status
Absolute Contraindication	Patients with known hypersensitivity to the active substance, montelukast, or any component of the formulation.
Acute Condition	The medicine is contraindicated for use in the reversal of bronchospasm in acute asthma attacks or status asthmaticus.

---

Age-Specific Eligibility Rules

Eligibility depends on the patient's age and the specific condition. Adults and adolescents (ge 15 years) are eligible for all primary uses. Pediatric eligibility is defined by minimum age thresholds:

• Asthma: Eligible for chronic treatment in patients ge 12 months of age.
• Exercise-Induced Bronchoconstriction (EIB): Indicated for prevention in patients ge 6 years of age.
• Perennial Allergic Rhinitis (PAR): Indicated for patients ge 6 months of age.

Safety and effectiveness have not been established in pediatric patients below these minimum age thresholds. No dosage adjustment is required for geriatric patients.

---

Conditional Use and Restrictions

• Organ Function: No dosage adjustment is necessary for patients with renal insufficiency or mild-to-moderate hepatic impairment. Data for patients with severe hepatic impairment have not been assessed.
• Pregnancy/Lactation: Use during pregnancy or while breastfeeding is permitted only if clearly essential or clearly needed, due to limited controlled data.
• Allergic Rhinitis (U.S. Labeling): Use for allergic rhinitis is recommended to be reserved for patients who have an inadequate response or intolerance to alternative therapies.
• Formulation Warning: Chewable tablets contain phenylalanine (from aspartame), requiring caution for individuals with Phenylketonuria (PKU).

Interactions with other medicines and products

The official interaction profile for Montelukast (Синглон) is based on formal pharmacokinetic and pharmacodynamic studies documented in regulatory labels. These interactions define how the drug’s systemic exposure and effects are altered by co-administered substances.

Exposure-Altering Medicinal Products

Interaction Type	Interacting Product	Regulatory Finding
Exposure Increase	Gemfibrozil	Increases Montelukast systemic exposure (AUC) by approximately 4.4-fold due to CYP 2C8 and 2C9 inhibition.
Exposure Decrease	Phenobarbital, Rifampicin, Phenytoin	Hepatic enzyme inducers that decrease Montelukast concentrations (e.g., Phenobarbital reduces AUC by about 40%).
No Effect Noted	Theophylline, Prednisone, Warfarin	Montelukast has no clinically important effect on the pharmacokinetics of these agents.

The regulatory documentation notes a specific pharmacodynamic restriction: Montelukast has not been shown to mitigate the bronchoconstrictor response to Aspirin or Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in patients with known aspirin-sensitive asthma; continued avoidance of these agents is necessary for this population. Furthermore, a physical-chemical interaction is documented for the oral granule formulation, where co-administration with a high-fat meal reduces the drug's peak concentration (Cmax) by 35%. Finally, official caution is noted for the pediatric population when co-administering potent CYP inducers due to the risk of reduced Montelukast exposure.

The action of Синглон (Montelukast) is defined by its highly specific molecular intervention within the leukotriene signaling cascade, resulting in predictable physiological adjustments in the respiratory system.

Selective CysLT1 Receptor Blockade

The mechanism is initiated by the drug acting as a highly selective antagonist at the Cysteinyl Leukotriene Receptor Type 1 (CysLT1 Receptor). This molecular interaction blocks the binding of the body's potent inflammatory chemicals, the cysteinyl leukotrienes, thereby suppressing the primary signaling steps associated with leukotriene-mediated cellular activation.

Modulation of Airway Muscle Tone and Cellular Recruitment

This molecular blockade immediately affects the physiological responses of airway tissues. By preventing leukotriene signals from reaching the receptor, the mechanism results in a reduction in airway smooth muscle contraction and decreased vascular permeability (edema) associated with the inflammatory cascade. Furthermore, it modulates the signaling that drives the recruitment of inflammatory cells like eosinophils into the airways, decreasing the proliferation and activation of these cells.

Contextual Scope and Limitation

The physiological consequences are shaped by its precise targeting of the CysLT pathway. This mechanism is relevant in systems where this specific inflammatory mediator dominates, but its physiological scope is limited to the CysLT pathway; it does not modulate activation driven by other primary mediators, such as histamine or prostaglandins.

Official Administration Guidelines

Montelukast sodium (Синглон) is an orally administered medication provided in film-coated tablets, chewable tablets, and oral granules. The standard regimen for continuous management involves a single dose taken once daily. Dosing is tailored by age and indication, but the standard maintenance dose for adults and adolescents (15 years of age and older) is 10 mg.

For chronic conditions such as asthma, the daily dose is typically administered in the evening to maintain a consistent systemic concentration. If the medication is used solely for the symptoms of allergic rhinitis, administration may occur in the morning or evening. Pediatric dosing, utilizing the 4 mg or 5 mg strengths, is determined by the patient's age and specific indication.

Usage patterns differ based on the therapeutic context. For the prevention of exercise-induced bronchoconstriction (EIB), a single 10 mg dose is taken at least 2 hours prior to exercise. Importantly, if a patient is already taking a daily maintenance dose, no additional pre-exercise dose should be taken.

Administration of the oral granules requires adherence to specific instructions: the packet contents must be administered within 15 minutes of opening. The granules can be consumed directly or mixed with a spoonful of permitted soft foods or specific cold liquids, but they must not be mixed with other beverages. If a routine dose is missed, the procedure is to skip the missed dose and resume the regular schedule; the dose should not be doubled. Dosing adjustments are not necessary for older adults or patients with mild-to-moderate hepatic or renal impairment.

Синглон (Montelukast): Recent Clinical Evidence

Синглон is a leukotriene receptor antagonist (LTRA) approved for the prophylaxis and chronic treatment of asthma, the prevention of exercise-induced bronchoconstriction (EIB), and the relief of symptoms of allergic rhinitis.

Clinical trials have consistently shown that montelukast, as monotherapy or add-on therapy, can contribute to improved asthma control. In controlled studies across various age groups, treatment was associated with improvements in key pulmonary function measures, such as Forced Expiratory Volume in 1 second (FEV1), and a reduction in the need for short-acting beta2-agonist rescue medication.

• Chronic Asthma: Research indicates that montelukast can be used alongside inhaled corticosteroids (ICS) and may facilitate a reduction in the required ICS dose for some patients, while maintaining asthma control. Its effectiveness compared to ICS monotherapy is generally observed to be lower.
• Exercise-Induced Bronchoconstriction (EIB): Studies confirm the drug's role in preventing EIB when taken prior to exercise, demonstrating a statistically significant attenuation of the fall in lung function (FEV1) following physical exertion.
• Allergic Rhinitis: Evidence from randomized, placebo-controlled trials suggests that montelukast is effective in alleviating symptoms of both seasonal and perennial allergic rhinitis, including nasal congestion and rhinorrhoea. When used in combination with an antihistamine, it may provide greater symptomatic improvement than either agent alone.

While the drug is generally reported to be well-tolerated, the US Food and Drug Administration (FDA) has noted the potential for neuropsychiatric adverse events, including agitation, depression, and sleep disturbances, which underscores the importance of patient monitoring. The clinical evidence on efficacy and safety continues to inform its use within global treatment guidelines.

Key Studies & References

1. Montelukast for chronic asthma in adults and children: systematic review and meta-analysis

Common questions about Синглон (FAQ)

---

Q: Can children take Синглон?

Regulatory documents confirm that Синглон is approved for use in pediatric patients for specific conditions. The official product information sets minimum age thresholds depending on the indication: chronic asthma treatment starts from 12 months, perennial allergic rhinitis from 6 months, and prevention of exercise-induced bronchoconstriction from 6 years. Dosing for pediatric patients is specifically based on age and the treated condition.

---

Q: Does Синглон treat the cause of the allergy or only relieve the symptoms?

Синглон is classified as an anti-inflammatory medication, known as a Leukotriene Receptor Antagonist. Its mechanism is to block the effects of inflammatory chemicals (leukotrienes) that contribute to symptoms in asthma and allergic rhinitis. Official information states the drug is intended for long-term control and maintenance treatment; its role is to manage the condition and relieve symptoms, not to cure the underlying disease.

---

Q: Does Синглон affect the ability to drive a car?

Official safety information generally states that the medicine has no or negligible influence on the ability to drive or operate machinery. However, because some individuals have reported side effects such as drowsiness or dizziness (uncommon side effects), patients should exercise caution until they know how the medication affects them, especially concerning activities requiring mental alertness.

---

Q: What should be done if a rash appears while taking Синглон?

Adverse events documented in official labeling include rash and other signs of hypersensitivity reactions. If a rash or any severe or unusual symptoms are experienced, the official guidance for such adverse events generally indicates that the medication should be discontinued and a healthcare professional consulted.

---

Q: Is there a risk of developing dependence on Синглон?

According to regulatory safety documents, terms such as drug dependence or addiction are not listed among the known adverse reactions or risks associated with the use of Синглон.

---

Q: What happens if I suddenly stop taking Синглон?

Official warnings state that the medicine should not be abruptly stopped or substituted for other corticosteroid medications. Since this is a maintenance medicine for chronic conditions, any modifications to the prescribed regimen, including discontinuing the drug, are required to be made under the guidance of a healthcare professional.

---

Q: Can I take Синглон if I am taking antibiotics?

While many medicines do not interact, regulatory documents note that some drugs can affect the concentration of Синглон in the blood. For instance, the antibiotic Rifampicin is listed as an enzyme inducer that can potentially decrease the effectiveness of Синглон. It is important that a healthcare provider be informed about all medications, including antibiotics, currently being taken.

---

Q: Are there data on the use of Синглон in athletes?

Yes, one of the drug's official indications is for the prevention of exercise-induced bronchoconstriction (EIB). For this purpose, specific guidelines address administration timing before physical activity. Official administration guidelines specify that if a patient is already taking a daily maintenance dose, no additional pre-exercise dose is required.

---

Q: Can I take Синглон if I have other chronic diseases?

Regulatory information indicates that dosage adjustments are not typically required for patients with kidney problems or mild-to-moderate liver impairment. However, safety data are not available for patients with severe liver impairment. Additionally, patients with Phenylketonuria (PKU) should note that chewable tablets contain phenylalanine. All pre-existing chronic conditions should be discussed with a medical professional.

---

Q: Are there any foods or drinks to avoid when taking Синглон?

For the standard tablet form, there are generally no restrictions regarding food or drink. However, if the oral granule formulation is used, there are specific administration rules. The granules must not be mixed with any liquid other than baby formula or breast milk, and a high-fat meal may also reduce the drug's concentration.

How to Store and Dispose of Синглон?

This section outlines the official requirements for storing, handling, and disposing of Синглон (montelukast sodium), based on regulatory documentation.

Storage and Handling Requirements

Feature	Requirement
Temperature	Store at 20 C to 25 C (68 F to 77 F), with permitted excursions.
Protection	Keep in the original packaging, protected from both moisture and light.
Child Safety	Store away from children's reach.
Oral Granules Use	Do not open the packet until ready to use. After opening or mixing the granules with food, breast milk, or formula, the entire dose must be administered within 15 minutes.
Oral Granules Storage	Do not store mixed or unused portions of oral granules for later use; discard immediately.

Disposal Instructions

Dispose of this medication, its packaging, and any unused or expired portions according to the guidance provided by your federal, state, and local regulations. To prevent environmental contamination, it is advised to avoid discharging the product into drains or water courses.